Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM
| Authors |
Edith Schneider Anna Staffas Linda Röhner Kathrin Krowiorz Michael Heuser Konstanze Döhner Lars Bullinger Hartmut Döhner Linda Fogelstrand Arefeh Rouhi Florian Kuchenbauer Lars Palmqvist |
|---|---|
| Published in | Experimental hematology |
| Volume | 44 |
| Issue | 12 |
| Pages | 1166-71 |
| ISSN | 1873-2399 |
| Publication year | 2016 |
| Published at |
Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine |
| Pages | 1166-71 |
| Language | en |
| Links |
dx.doi.org/10.1016/j.exphem.2016.08... |
| Keywords | AML, MLL, miRNA |
| Subject categories | Molecular medicine (genetics and pathology), Molecular biology, Hematology |
MicroRNA-155 (miR-155) is an oncogenic miRNA upregulated in various tumor types and leukemias and has been suggested as a potential drug target. Based on our previous work detecting high miR-155 levels in response to Meis1 overexpression in a murine Hox leukemia model, we show here the relationship among HOXA9, MEIS1, and miR-155 levels in MLL-translocated acute myeloid leukemia (AML) patients. Using mouse bone marrow cells transformed by MLL-fusion genes expressing graduated levels of Meis1, we show a positive correlation between miR-155 and Meis1. However, using a miR-155-knockout mouse model, we show that the absence and the depletion of miR-155 have no effect on leukemia formation or progression. We also show for the first time that miR-155 levels are correlated with MLL translocations, but that miR-155 expression is dispensable for the formation of AML and has no effect on leukemia progression.
© UNIVERSITY OF GOTHENBURG • Sweden • Box 100 • SE-405 30 Gothenburg
Phone: +46 31 786 0000 • Contact • Organisation number: 202100-3153
About the website
Facebook
Twitter
Instagram
Youtube
Weibo